Review article: Is there an optimal therapeutic regimen for antimitochondrial antibody-negative primary biliary cirrhosis (autoimmune cholangitis)?

Alimentary Pharmacology and Therapeutics

Volumn 17, Issue 1, 2003, Pages 17-27

  Gisbert, J P ^b   Jones, E A ^a   Pajares, J M ^c   Moreno Otero, R ^c  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AZATHIOPRINE; BILIRUBIN; CORTICOSTEROID; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; MITOCHONDRION ANTIBODY; PREDNISOLONE; STEROID; URSODEOXYCHOLIC ACID;

ANTIBODY DETECTION; ANTIBODY TITER; AUTOIMMUNE DISEASE; BILIRUBIN BLOOD LEVEL; CHOLANGITIS; CLINICAL EXAMINATION; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LABORATORY TEST; OSTEOPOROSIS; PATHOLOGIC FRACTURE; PATIENT SELECTION; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; REMISSION; REVIEW; RISK ASSESSMENT; SERODIAGNOSIS; SURVIVAL; TREATMENT OUTCOME;

ANTIBODIES; CHOLANGITIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER CIRRHOSIS, BILIARY; MITOCHONDRIA, LIVER; TREATMENT OUTCOME; URSODEOXYCHOLIC ACID;

EID: 0037250591     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2003.01381.x     Document Type: Review

References (62)

1. Kaplan MM. Primary biliary cirrhosis. N Engl J Med 1996; 335: 1570-80.
2. Sherlock S. Primary biliary cirrhosis. primary sclerosing cholangitis, and autoimmune cholangitis. Clin Liver Dis 2000; 4: 97-113.
3. Kenny RP, Czaja AJ, Ludwig J, Dickson ER. Frequency and significance of antimitochondrial antibodies in severe chronic active hepatitis. Dig Dis Sci 1986; 31: 705-11.
4. Michieletti P, Wanless IR, Katz A, et al. Antimitochondrial antibody negative primary biliary cirrhosis: a distinct syndrome of autoimmune cholangitis. Gut 1994; 35: 260-5.
5. Taylor SL, Dean PJ, Riely CA. Primary autoimmune cholangitis. An alternative to antimitochondrial antibody-negative primary biliary cirrhosis. Am J Surg Pathol 1994; 18: 91-9.
6. Ben-Ari Z, Dhillon AP. Sherlock S. Autoimmune cholangiopathy: part of the spectrum of autoimmune chronic active hepatitis. Hepatology 1993; 18: 10-5.
7. Sánchez-Pobre P, Castellano G, Colina F. et al. Antimitochondrial antibody-negative chronic nonsuppurative destructive cholangitis. Atypical primary biliary cirrhosis or autoimmune cholangitis? J Clin Gastroenterol 1996; 23: 191-8.
8. Kloppel G. Kirchhof M. Berg PA. Natural course of primary biliary cirrhosis. I. A morphological, clinical and serological analysis of 103 cases. Liver 1982; 2: 141-51.
9. Poupon R. Chazouilleres O, Poupon RE. Chronic cholestatic diseases. J Hepatol 2000; 32: 129-40.
10. Kim WR, Ludwig J, Lindor KD. Variant forms of cholestatic diseases involving small bile ducts in adults. Am J Gastroenterol 2000; 95: 1130-8.
11. Medina J. Jones EA, Garcia-Monzon C. Moreno-Otero R. Immunopathogenesis of cholestatic autoimmune liver diseases. Eur J Clin Invest 2001; 31: 64-71.
12. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Autoimmune cholangitis within the spectrum of autoimmune liver disease. Hepatology 2000; 31: 1231-8.
13. Goodman ZD, McNally PR, Davis DR. Ishak KG. Autoimmune cholangitis: a variant of primary biliary cirrhosis. Clinico-pathologic and serologic correlations in 200 cases. Dig Dis Sci 1995; 40: 1232-42.
14. Invernizzi P, Crosignani A, Battezzati PM, et al. Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosis. Hepatology 1997; 25: 1090-5.
15. Nakanuma Y, Harada K, Kaji K, et al. Clinicopathological study of primary biliary cirrhosis negative for antimitochondrial antibodies. Liver 1997; 17: 281-7.
16. Lacerda MA, Ludwig J, Dickson ER, Jorgensen RA, Lindor KD. Antimitochondrial antibody-negative primary biliary cirrhosis. Am J Gastroenterol 1995; 90: 247-9.
17. Masuda J, Omagari K, Matsuo I, et al. Changes in titers of antimitochondrial and antinuclear antibodies during the course of primary biliary cirrhosis. J Gastroenterol Hepatol 2001; 16: 239-43.
18. Neuberger J, Thomson R. PBC and AMA - what is the connection? Hepatology 1999; 29: 271-6.
19. Nakajima M, Shimizu H. Miyazaki A, Watanabe S, Kitami N, Sato N. Detection of IgA. IgM. and IgG subclasses of anti-M2 antibody by immunoblotting in autoimmune cholangitis: is autoimmune cholangitis an early stage of primary biliary cirrhosis? J Gastroenterol 1999; 34: 607-12.
20. Kim WR, Poterucha JJ, Jorgensen RA, et al. Does antimitochondrial antibody status affect response to treatment in patients with primary biliary cirrhosis? Outcomes of ursode-oxycholic acid therapy and liver transplantation. Hepatology 1997; 26: 22-6.
21. Miyakawa H, Tanaka A, Kikuchi K, et al. Detection of antimitochondrial autoantibodies in immunofluorescent AMA-negative patients with primary biliary cirrhosis using recombinant autoantigens. Hepatology 2001; 34: 243-8.
22. Colombato LA, Alvarez F, Cote J, Huet PM. Autoimmune cholangiopathy: the result of consecutive primary biliary cirrhosis and autoimmune hepatitis? Gastroenterology 1994; 107: 1839-43.
23. Cho YJ, Han DS, Kim TY, et al. Negative conversion of anti-mitochondrial antibody in primary biliary cirrhosis: a case of autoimmune cholangitis. J Korean Med Sci 1999; 14: 102-6.
24. Solis Herruzo JA. Autoimmune cholangiopathy. Gastroenterol Hepatol 1996; 19: 213-6.
25. Ludwig J. The pathology of primary biliary cirrhosis and autoimmune cholangitis. Baillieres Best Pract Res Clin Gastroenterol 2000; 14: 601-13.
26. Heathcote J. Autoimmune cholangitis. Gut 1997; 40: 440-2.
27. Gordon SC, Quattrociocchi-Longe TM, Khan BA, et al. Anti-bodies to carbonic anhydrase in patients with immune cholangiopathies. Gastroenterology 1995; 108: 1802-9.
28. Muratori P, Muratori L, Lenzi M, Bianchi FB. Antibodies to carbonic anhydrase in autoimmune cholangiopathy. Gastroenterology 1997; 112: 1053-4.
29. Akisawa N, Nishimori I, Miyaji E, et al. The ability of anti-carbonic anhydrase II antibody to distinguish autoimmune cholangitis from primary biliary cirrhosis in Japanese patients. J Gastroenterol 1999; 34: 366-71.
30. Invernizzi P. Battezzati PM, Crosignani A, et al. Antibody to carbonic anhydrase II is present in primary biliary cirrhosis (PBC) irrespective of antimitochondrial antibody status. Clin Exp Immunol 1998; 114: 448-54.
31. Poupon RE, Bonnand AM, Chretien Y, Poupon R. Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. The UDCA-PBC Study Group. Hepatology 1999; 29: 1668-71.
32. Corpechot C, Carrat F, Bonnand AM. Poupon RE. Poupon R. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology 2000; 32: 1196-9.
33. Pares A, Caballeria L, Rodes J, et al. Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver. J Hepatol 2000; 32: 561-6.
34. Czaja AJ. Treatment of autoimmune hepatitis. In: Arroyo V, Bosch J, Bruix J, Ginés P, Navasa M, Rodés J. eds. Therapy in Hepatology. Barcelona: Ars Médica, 2001: 99-108.
35. Ishibashi H. Are primary biliary cirrhosis and autoimmune cholangitis reflective of the pendulum of a clock and therefore represent a 'phase' of the same disease? J Gastroenterol Hepatol 2001; 16: 121-3.
36. Li CP, Hwang SJ, Chan CY, et al. Clinical evaluation of primary biliary cirrhosis in Chinese patients without serum anti-mitochondrial antibody. Chung Hua I Hsueh Tsa Chih (Taipei) 1997; 59: 334-40.
37. Saló J, Caballería L, Bruguera M, Parés A, Rodés J. Autoimmune cholangitis or primary biliary cirrhosis without anti-mitochondrial antibodies? Gastroenterol Hepatol 1997; 20: 5-10.
38. Kinoshita H, Omagari K, Whittingham S, et al. Autoimmune cholangitis and primary biliary cirrhosis - an autoimmune enigma. Liver 1999; 19: 122-8.
39. Poupon RE, Lindor KD, Cauch-Dudek K, Dickson ER, Poupon R, Heathcote EJ. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997; 113: 884-90.
40. Goulis J, Leandro G, Burroughs AK. Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis. Lancet 1999; 354: 1053-60.
41. Omagari K, Ikuno N, Matsuo I, et al. Autoimmune cholangitis syndrome with a bias towards primary biliary cirrhosis. Pathology 1996; 28: 255-8.
42. Mohr L, Heintges T, Hensel F, Niederau C, Haussinger D. Treatment of autoimmune cholangitis. Dig Dis Sci 1998; 43: 2160-3.
43. Primo J, Miralles A, Ferrando J, et al. Atypical primary biliary cirrhosis or autoimmune cholangitis? Gastroenterol Hepatol 1999; 22: 505-9.
44. Romero Gomez M, Wichmann I, Otero Fernandez MA, et al. Anti-Sp100 and anti-Gp210 in the diagnosis of primary biliary cirrhosis in patients with autoimmnne cholangitis. Gastroenterol Hepatol 1999; 22: 11-3.
45. Devesa F, Ferrando MJ, Bustamante M, et al. Autoimmune cholangitis or autoimmune hepatitis with cholestatic component. Gastroenterol Hepatol 2001; 24: 143-4.
46. Geubel AP, Baggenstoss AH, Summerskill WH. Responses to treatment can differentiate chronic active liver disease with cholangitic features from the primary biliary cirrhosis syndrome. Gastroenterology 1976; 71: 444-9.
47. Mitchison HC, Bassendine MF, Malcolm AJ, Watson AJ, Record CO, James OF. A pilot, double-blind, controlled 1-year trial of prednisolone treatment in primary biliary cirrhosis: hepatic improvement but greater bone loss. Hepatology 1989; 10: 420-9.
48. Brunner G. Klinge O. A chronic destructive non-suppurative cholangitis-like disease picture with antinuclear antibodies (immunocholangitis). Dtsch Med Wochenschr 1987; 112: 1454-8.
49. Marinho R, Graca H, Ramalho F, Costa A, Batista A. de Moura MC. Autoimmune cholangitis: case report. Hepatogastroenterology 1999; 46: 1949-52.
50. Czaja AJ. Frequency and nature of the variant syndromes of autoimmune liver disease. Hepatology 1998; 28: 360-5.
51. Sherlock S. Ludwig Symposium on biliary disorders. Auto-immune cholangitis: a unique entity? Mayo Clin Proc 1998; 73: 184-90.
52. Mitry E, Algayres JP, Bili H, et al. Autoimmune cholangitis successfully treated with corticotherapy. One case. Gastroenterol Clin Biol 1998; 22: 94-7.
53. Masumoto T, Ninomiya T, Michitaka K, et al. Three patients with autoimmune cholangiopathy treated with prednisolone. J Gastroenterol 1998; 33: 909-13.
54. Ogata H. Tsuji H. Hashiguchi M, Azuma K, Shimono J, Fujishima M. Autoimmune cholangiopathy associated with rheumatoid arthritis. Hepatogastroenterology 2000; 47: 1533-4.
55. Castro F, Narvaez F, Vilaseca J, Autoinmune cholangitis with good response to corticoids. Gastroenterol Hepatol 2001; 24: 462.
56. Ben-Ari Z, Czaja AJ. Autoimmune hepatitis and its variant syndromes. Gut 2001; 49: 589-94.
57. Czaja AJ. The variant forms of autoimmune hepatitis. Ann Intern Med 1996; 125: 588-98.
58. Mackay IR. Autoimmune disease overlaps and the liver: two for the price of one? J Gastroenterol Hepatol 2000; 15: 3-8.
59. Li CP, Tong MJ, Hwang SJ. et al. Autoimmune cholangitis with features of autoimmune hepatitis: successful treatment with immunosuppressive agents and ursodeoxycholic acid. J Gastroenterol Hepatol 2000; 15: 95-8.
60. Chazouilleres O, Wendum D. Serfaty L, Montembault S, Rosmorduc O, Poupon R. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology 1998; 28: 296-301.
61. Lohse AW, zum Buschenfelde KH, Franz B. Kanzler S, Gerken G. Dienes HP. Characterization of the overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis: evidence for it being a hepatitic form of PBC in genetically susceptible individuals. Hepatology 1999; 29: 1078-84.
62. Joshi S, Cauch-Dudek K, Wanless JR. et al. Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid. Hepatology 2002; 35: 409-13.